16.01.2013 • News

Lonza, BaroFold Announce Technology Evaluation Agreement for PreEMT

Lonza, a leader in biological development and BaroFold, an protein technology developer, announced today a non-exclusive technology and license agreement whereby Lonza will evaluate BaroFold's PreEMT high pressure refolding technology for use in biological development refolding processes. Lonza's evaluation will focus on refolding difficult to express microbial products expressed as inclusion bodies. The PreEMT unit will be installed for evaluation at Lonza's microbial development and manufacturing plant in Visp, Switzerland.

The agreement includes an option for Lonza to extend the platform evaluation to GMP production analysis.

 

Interview

Driving Transformation
Interconnected Global Chemicals Logistics

Driving Transformation

DP World is reshaping global chemical supply chains. Christene Smith of CHEManager interviews Markus Kanis, Global SVP Chemicals, on the company’s roadmap, new technologies, and the evolving demands of global trade.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read